Menu

Lavish Spending at MD Anderson

The public cancer center is criticized for allegedly devoting at least $1.5 million to remodeling an executive suite.

May 28, 2013
Kate Yandell

FLICKR, FAUNGGAn investigation by The Cancer Letter reveals that the University of Texas MD Anderson Cancer Center may have spent at least $1.5 million dollars on a project to remodel a suite of office and meeting spaces for Lynda Chin, chair of MD Anderson’s department of genomic medicine and scientific director of the new Institute for Applied Cancer Science (IACS). Chin is also the wife of Ronald DePinho, MD Anderson’s president.

MD Anderson disputes the report, saying that the office renovations cost $547,434 and that the higher figure of $1.5 million included lab equipment such as fume hoods and ventilation.

The Cancer Letter based its assertions on 680 pages of internal documents it obtained through the Texas Public Information Act. The purchases included a total of $210,000 worth of glass walls and doors to “provide a feeling of transparency,” according to the documents. It also includes two settees worth $7,754 and $6,961, two $5,000 credenzas, and other expensive furniture. The money came from MD Anderson’s capital project funds, which are “derived from investment income, philanthropy, and patient revenue,” according to an MD Anderson statement sent to The Cancer Letter.

The renovations were supposed to make the suite look more “corporate,” according to the documents. The goal of the IACS is to forge partnerships between the center and pharmaceutical companies to create better cancer drugs. “The renovations of space for the Institute for Applied Cancer Science and Department of Genomic Medicine—both new entities for MD Anderson—transformed a traditional academic office suite to a work environment and meeting area for a science/business enterprise, a concept new not only to MD Anderson, but most of academic medicine,” MD Anderson’s statement said.

The revelation comes at a time when MD Anderson is facing some financial troubles. DePinho announced earlier this month in a letter to employees that the center had been spending more than it had been earning and would be cutting expenses by freezing salaries, slowing hiring, and postponing some projects, The Cancer Letter said.

Hat tips to Nature and ScienceInsider.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing